Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

619 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group.
Fujiwara Y, Urata T, Niiya D, Yano T, Nawa Y, Yoshida I, Imai T, Sunami K, Fujii S, Ennishi D, Maeda Y, Hiramatsu Y. Fujiwara Y, et al. Among authors: yoshida i. Int J Hematol. 2022 Jun;115(6):811-815. doi: 10.1007/s12185-022-03363-3. Epub 2022 May 18. Int J Hematol. 2022. PMID: 35583725
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
Maeda Y, Nishimori H, Yoshida I, Hiramatsu Y, Uno M, Masaki Y, Sunami K, Masunari T, Nawa Y, Yamane H, Gomyo H, Takahashi T, Yano T, Matsuo K, Ohshima K, Nakamura S, Yoshino T, Tanimoto M. Maeda Y, et al. Among authors: yoshida i. Haematologica. 2017 Dec;102(12):2097-2103. doi: 10.3324/haematol.2017.167742. Epub 2017 Sep 29. Haematologica. 2017. PMID: 28971899 Free PMC article. Clinical Trial.
Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma.
Maruyama D, Tsukasaki K, Uchida T, Maeda Y, Shibayama H, Nagai H, Kurosawa M, Suehiro Y, Hatake K, Ando K, Yoshida I, Hidaka M, Murayama T, Okitsu Y, Tsukamoto N, Taniwaki M, Suzumiya J, Tamura K, Yamauchi T, Ueda R, Tobinai K. Maruyama D, et al. Among authors: yoshida i. Ann Hematol. 2019 Jan;98(1):131-142. doi: 10.1007/s00277-018-3418-2. Epub 2018 Jul 5. Ann Hematol. 2019. PMID: 29974231 Free PMC article. Clinical Trial.
Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial.
Ohmachi K, Tobinai K, Kinoshita T, Ishikawa T, Hatake K, Ichikawa S, Ohmine K, Kamitsuji Y, Choi I, Chou T, Tsukasaki K, Kumagai K, Taniwaki M, Uchida T, Kikukawa Y, Kubo K, Mihara K, Tsukamoto N, Izutsu K, Yoshida I, Ishida F, Usui N, Iida S, Murayama T, Ueda E, Kuriki H, Ando K. Ohmachi K, et al. Among authors: yoshida i. Int J Hematol. 2018 Nov;108(5):499-509. doi: 10.1007/s12185-018-2497-0. Epub 2018 Jul 19. Int J Hematol. 2018. PMID: 30027429 Clinical Trial.
Consolidation with 90 Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma.
Miura K, Tsujimura H, Masaki Y, Iino M, Takizawa J, Maeda Y, Yamamoto K, Tamura S, Yoshida A, Yagi H, Yoshida I, Kitazume K, Masunari T, Choi I, Kakinoki Y, Suzuki R, Yoshino T, Nakamura S, Hatta Y, Yoshida T, Kanno M. Miura K, et al. Among authors: yoshida i, yoshida t, yoshida a. Hematol Oncol. 2021 Feb;39(1):51-59. doi: 10.1002/hon.2809. Epub 2020 Oct 7. Hematol Oncol. 2021. PMID: 32978820 Clinical Trial.
Correction to: Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma.
Maruyama D, Tsukasaki K, Uchida T, Maeda Y, Shibayama H, Nagai H, Kurosawa M, Suehiro Y, Hatake K, Ando K, Yoshida I, Hidaka M, Murayama T, Okitsu Y, Tsukamoto N, Taniwaki M, Suzumiya J, Tamura K, Yamauchi T, Ueda R, Tobinai K. Maruyama D, et al. Among authors: yoshida i. Ann Hematol. 2018 Dec;97(12):2529-2530. doi: 10.1007/s00277-018-3455-x. Ann Hematol. 2018. PMID: 30054705 Free PMC article.
Phase II study of dose-adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B-cell lymphoma patients.
Yamasaki S, Kada A, Choi I, Iida H, Sekiguchi N, Harada N, Sawamura M, Shimomura T, Komeno T, Yano T, Yoshida I, Yoshida S, Sunami K, Hishita T, Takatsuki H, Ohshima K, Takeshita M, Saito AM, Iwasaki H, Nagai H. Yamasaki S, et al. Among authors: yoshida i, yoshida s. EJHaem. 2020 Oct 15;1(2):507-516. doi: 10.1002/jha2.111. eCollection 2020 Nov. EJHaem. 2020. PMID: 35844987 Free PMC article.
Phase II study of intensified rituximab induction and maintenance for low grade B cell lymphoma.
Nagai H, Shimomura T, Takeuchi M, Hanada S, Komeno T, Sunami K, Hidaka M, Yano T, Kitano K, Yoshida I, Inoue N, Saito A, Horibe K, Motitani S, Ichihara S, Watanabe T, Sawamura M. Nagai H, et al. Among authors: yoshida i. Leuk Lymphoma. 2017 Dec;58(12):2845-2851. doi: 10.1080/10428194.2017.1319054. Epub 2017 May 16. Leuk Lymphoma. 2017. PMID: 28509595 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 31649127
619 results